Autres langues Biocon Limited

Actions

BIOCON

INE376G01013

Temps Différé NSE India S.E. Autres places de cotation 13:40:29 16/07/2024			Varia. 5j.	Varia. 1 janv.
353,4 ^INR	-1,60 %		-2,64 %	+41,56 %

28/06	L'Inde prévoit des mesures d'incitation pour les fabricants de médicaments contre le diabète et l'obésité en 2026, selon un responsable gouvernemental	RE
24/06	L'EMA approuve la nouvelle installation de Biocon Biologics en Inde et renouvelle les certifications BPF pour les sites d'Inde et de Malaisie	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

India plans incentives for diabetes, obesity drug makers in 2026, government official says	28/06
EMA Approves Biocon Biologics' New mAbs Facility in India and Renews GMP Certifications for India and Malaysia Sites	24/06
Biocon Arm Gets European Regulator's Nod to Manufacture Bevacizumab at Indian Facility	24/06
Biocon Gets Four Observations from US FDA for Visakhapatnam, India Facility	24/06
India's Biocon seeks partner to test generic Wegovy, Ozempic in China	20/06
Update On Aflibercept BPCIA Litigation	18/06
Biocon Gets Three Observations from US FDA after Visakhapatnam, India Unit Inspection	17/06
Indian Equities End Flat on Tuesday; ONGC Shares Rise 6%	11/06
Biocon Names Interim CFO	11/06
Biocon Limited Announces Appointment of Mukesh Kamath, Head - Business Finance R&D, as the Interim Chief Financial Officer	11/06
Biocon Foundation conducts awareness session in 14 Government Schools	07/06
AbbVie's tight grip on Humira market raises concerns about biosimilars	07/06
Biocon Limited Receives Approval from the U.S. Food and Drug Administration	03/06
Biocon Limited Receives Show Cause Notice from the Assistant Commissioner of Customs, Chennai	31/05
INDIA STOCKS-Indian shares surrender gains as U.S. rate worries weigh	24/05
Biocon Ties Up with Handok to Market Anti-Diabetic Drug Liraglutide in South Korea	24/05
Biocon Limited Signs Exclusive Licensing and Supply Deal for the Commercialization of Liraglutide in South Korea with Handok Inc	24/05
US FDA Approves Samsung Bioepis' Eye Disease Drug Opuviz	23/05
Biocon's Consolidated Net Profit Declines in Fiscal Q4	17/05
India's Biocon posts Q4 profit fall as higher raw material costs bite	16/05

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Biocon Limited

Actions

BIOCON

INE376G01013

Autres langues

Filtres